The Chavanod, France-based company labeled Intercil as the first in a brand-new class of glaucoma surgical procedure — cilioscleral interpositioning device (CID). It designed the device to lower intraocular pressure (IOP) by increasing uveoscleral outflow. However, it aims to achieve this without penetrating the anterior chamber of the eye.

According to a news release, the approach could preserve the integrity of the anterior chamber of the eye using a “no-bleb-no-cleft” approach. This offers potential benefits in minimizing the risk of corneal endothelial cell loss.

Key features include 360° positioning capabilities around the eye to ensure optimal placement. It has suitability for narrow-angle glaucoma patients along with standalone effectiveness in primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG).